Libourne, May 5th, 2026 — Ceva Animal Health (Ceva), the world’s fifth largest animal health company, present in 110 countries, today announces the appointment of Ian Tarpey as Executive Vice President for Global Innovation and Research & Development, and a new member of the Executive Committee.
Throughout his career, he has contributed to shaping innovation strategies, advancing complex biological pipelines and supporting the development and registration of novel veterinary vaccines and therapeutics. His expertise spans immunology, infectious diseases and biologics, as well as R&D governance, portfolio management and external collaborations. Ian Tarpey holds a PhD in Immunology from King’s College London and an MBA from The Open University (UK).
In his new role at Ceva, he will be responsible for defining and executing the Group’s innovation and R&D strategy. He will focus on strengthening the connection between R&D and customer needs, fostering agility to accelerate innovation.Ian Tarpey, newly appointed EVP for Global Innovation and R&D , said “I am honoured to join Ceva at such a pivotal moment for the company. Ceva’s strong entrepreneurial culture, long-standing commitment to innovation and global footprint in animal health create a unique environment to deliver meaningful scientific progress. I look forward to working with the teams to accelerate innovation for the benefit of customers, animals and the wider industry.”
Pascal Anjot, who previously held this function, is appointed Executive Vice President for Global Livestock Franchises. He will oversee global marketing activities for farm animals and the Scientific Support and Investigation Units (SSIU), which provide advanced diagnostics and tailored customer support, particularly in the detection of emerging diseases and variants.
This organisation reflects Ceva’s determination to further strengthen its performance, resilience and innovation capabilities, while preserving the commitment of its teams and its unique entrepreneurial culture.